首页 > 最新文献

Investigative and Clinical Urology最新文献

英文 中文
Analysis of sleep pattern in patients with nocturnal enuresis: A prospective, observational, pilot study. 夜间遗尿症患者的睡眠模式分析:一项前瞻性观察试验研究。
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-11-01 DOI: 10.4111/icu.20240280
Dong-Gi Lee, Seong Cheol Kim

Purpose: This study aimed to analyze the sleep patterns of patients with nocturnal enuresis (NE) using a wearable brain-wave-sensing device.

Materials and methods: We prospectively analyzed 10 of the 14 patients who visited the hospital for NE between August 2023 and July 2024 and agreed to participate in the study. Four patients were excluded owing to pairing errors and loss to follow-up. Participants were instructed to maintain a frequency volume chart for 1 week and sleep while wearing MUSE-S™, a wearable brain-wave detection device. We monitored the arousal threshold state based on sleep patterns when NE occurred in all patients.

Results: The median age of the patients was 8.7 years (interquartile range, 7.0-10.6), and 4 patients (40.0%) were male. In all participants, non-rapid eye movement (NREM) deep sleep was the dominant stage in the early part of sleep, whereas NREM light sleep was dominant in the middle part. The arousal threshold was high in the early part of sleep and decreased toward the end. A poor response to enuretic alarms was observed when NE occurred during the NREM deep-dominant period. In contrast, a good response was observed when NE occurred during the NREM light-dominant period.

Conclusions: Differences in sleep stages influence the arousal threshold more than individual characteristics. To effectively manage the NE, focusing on the timing of urination is important in the latter part of the sleep period.

目的:本研究旨在使用可穿戴脑电波传感设备分析夜遗尿症(NE)患者的睡眠模式:我们对 2023 年 8 月至 2024 年 7 月期间因 NE 到医院就诊并同意参与研究的 14 名患者中的 10 名进行了前瞻性分析。有四名患者因配对错误和失去随访而被排除在外。研究人员要求参与者在佩戴可穿戴脑电波检测设备 MUSE-S™ 的情况下保持频率音量表一周并睡觉。我们根据所有患者发生NE时的睡眠模式监测唤醒阈值状态:患者的中位年龄为 8.7 岁(四分位数间距为 7.0-10.6),其中 4 名患者(40.0%)为男性。在所有参与者中,非快速眼动(NREM)深睡眠是睡眠早期的主要阶段,而非快速眼动浅睡眠则是睡眠中期的主要阶段。唤醒阈值在睡眠早期较高,在睡眠末期逐渐降低。当NE发生在NREM深睡眠主导期时,对遗尿警报的反应较差。与此相反,当NE发生在NREM轻度主导期时,则反应良好:结论:睡眠阶段的差异对唤醒阈值的影响大于个体特征。结论:睡眠阶段的差异对唤醒阈值的影响大于个体特征。为了有效控制NE,在睡眠后期关注排尿时间非常重要。
{"title":"Analysis of sleep pattern in patients with nocturnal enuresis: A prospective, observational, pilot study.","authors":"Dong-Gi Lee, Seong Cheol Kim","doi":"10.4111/icu.20240280","DOIUrl":"10.4111/icu.20240280","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to analyze the sleep patterns of patients with nocturnal enuresis (NE) using a wearable brain-wave-sensing device.</p><p><strong>Materials and methods: </strong>We prospectively analyzed 10 of the 14 patients who visited the hospital for NE between August 2023 and July 2024 and agreed to participate in the study. Four patients were excluded owing to pairing errors and loss to follow-up. Participants were instructed to maintain a frequency volume chart for 1 week and sleep while wearing MUSE-S™, a wearable brain-wave detection device. We monitored the arousal threshold state based on sleep patterns when NE occurred in all patients.</p><p><strong>Results: </strong>The median age of the patients was 8.7 years (interquartile range, 7.0-10.6), and 4 patients (40.0%) were male. In all participants, non-rapid eye movement (NREM) deep sleep was the dominant stage in the early part of sleep, whereas NREM light sleep was dominant in the middle part. The arousal threshold was high in the early part of sleep and decreased toward the end. A poor response to enuretic alarms was observed when NE occurred during the NREM deep-dominant period. In contrast, a good response was observed when NE occurred during the NREM light-dominant period.</p><p><strong>Conclusions: </strong>Differences in sleep stages influence the arousal threshold more than individual characteristics. To effectively manage the NE, focusing on the timing of urination is important in the latter part of the sleep period.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":"65 6","pages":"587-592"},"PeriodicalIF":2.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543651/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142591036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The continuing legacy of Investigative and Clinical Urology. 泌尿外科研究与临床》的持续传承。
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-11-01 DOI: 10.4111/icu.6506ed
Kwangsung Park
{"title":"The continuing legacy of <i>Investigative and Clinical Urology</i>.","authors":"Kwangsung Park","doi":"10.4111/icu.6506ed","DOIUrl":"10.4111/icu.6506ed","url":null,"abstract":"","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":"65 6","pages":"525-526"},"PeriodicalIF":2.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543653/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142591085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Using machine learning to construct the diagnosis model of female bladder outlet obstruction based on urodynamic study data. 基于尿动力学研究数据,利用机器学习构建女性膀胱出口梗阻诊断模型。
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-11-01 DOI: 10.4111/icu.20240111
Quan Zhou, Guang Li, Kai Cui, Weilin Mao, Dongxu Lin, Zhenglong Yang, Zhong Chen, Youmin Hu, Xin Zhang

Purpose: To intelligently diagnose whether there is bladder outlet obstruction (BOO) in female with decent detrusor contraction ability by focusing on urodynamic study (UDS) data.

Materials and methods: We retrospectively reviewed the UDS data of female patients during urination. Eleven easily accessible urinary flow indicators were calculated according to the UDS data of each patient during voiding period. Eight diagnosis models based on back propagation neural network with different input feature combination were constructed by analyzing the correlations between indicators and lower urinary tract dysfunction labels. Subsequently, the stability of diagnostic models was evaluated by five-fold cross-validation based on training data, while the performance was compared on test dataset.

Results: UDS data from 134 female patients with a median age of 51 years (range, 27-78 years) were selected for our study. Among them, 66 patients suffered BOO and the remaining were normal. Applying the 5-fold cross-validation method, the model with the best performance achieved an area under the receiver operating characteristic curve (AUC) value of 0.949±0.060 using 9 UDS input features. The accuracy, sensitivity, and specificity for BOO diagnosis model in the testing process are 94.4%, 100%, and 89.3%, respectively.

Conclusions: The 9 significant indicators in UDS were employed to construct a diagnostic model of female BOO based on machine learning algorithm, which performs preferable classification accuracy and stability.

目的:通过关注尿动力学研究(UDS)数据,智能诊断具有良好逼尿肌收缩能力的女性是否存在膀胱出口梗阻(BOO):我们回顾性地查看了女性患者排尿时的 UDS 数据。根据每位患者排尿期间的 UDS 数据,计算出 11 个易于获得的尿流指标。通过分析指标与下尿路功能障碍标签之间的相关性,构建了八个基于反向传播神经网络、不同输入特征组合的诊断模型。随后,通过基于训练数据的五倍交叉验证评估了诊断模型的稳定性,并对测试数据集的性能进行了比较:研究选取了 134 名女性患者的 UDS 数据,中位年龄为 51 岁(27-78 岁)。其中,66 名患者患有 BOO,其余为正常人。采用 5 倍交叉验证法,使用 9 个 UDS 输入特征,性能最佳的模型的接收器工作特征曲线下面积(AUC)值为 0.949±0.060。在测试过程中,BOO 诊断模型的准确率、灵敏度和特异性分别为 94.4%、100% 和 89.3%:结论:利用 UDS 中的 9 个重要指标构建了基于机器学习算法的女性 BOO 诊断模型,该模型的分类准确性和稳定性较好。
{"title":"Using machine learning to construct the diagnosis model of female bladder outlet obstruction based on urodynamic study data.","authors":"Quan Zhou, Guang Li, Kai Cui, Weilin Mao, Dongxu Lin, Zhenglong Yang, Zhong Chen, Youmin Hu, Xin Zhang","doi":"10.4111/icu.20240111","DOIUrl":"10.4111/icu.20240111","url":null,"abstract":"<p><strong>Purpose: </strong>To intelligently diagnose whether there is bladder outlet obstruction (BOO) in female with decent detrusor contraction ability by focusing on urodynamic study (UDS) data.</p><p><strong>Materials and methods: </strong>We retrospectively reviewed the UDS data of female patients during urination. Eleven easily accessible urinary flow indicators were calculated according to the UDS data of each patient during voiding period. Eight diagnosis models based on back propagation neural network with different input feature combination were constructed by analyzing the correlations between indicators and lower urinary tract dysfunction labels. Subsequently, the stability of diagnostic models was evaluated by five-fold cross-validation based on training data, while the performance was compared on test dataset.</p><p><strong>Results: </strong>UDS data from 134 female patients with a median age of 51 years (range, 27-78 years) were selected for our study. Among them, 66 patients suffered BOO and the remaining were normal. Applying the 5-fold cross-validation method, the model with the best performance achieved an area under the receiver operating characteristic curve (AUC) value of 0.949±0.060 using 9 UDS input features. The accuracy, sensitivity, and specificity for BOO diagnosis model in the testing process are 94.4%, 100%, and 89.3%, respectively.</p><p><strong>Conclusions: </strong>The 9 significant indicators in UDS were employed to construct a diagnostic model of female BOO based on machine learning algorithm, which performs preferable classification accuracy and stability.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":"65 6","pages":"559-566"},"PeriodicalIF":2.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543646/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142591087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Application of deep learning for semantic segmentation in robotic prostatectomy: Comparison of convolutional neural networks and visual transformers. 在机器人前列腺切除术中应用深度学习进行语义分割:卷积神经网络与视觉转换器的比较。
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-11-01 DOI: 10.4111/icu.20240159
Sahyun Pak, Sung Gon Park, Jeonghyun Park, Hong Rock Choi, Jun Ho Lee, Wonchul Lee, Sung Tae Cho, Young Goo Lee, Hanjong Ahn

Purpose: Semantic segmentation is a fundamental part of the surgical application of deep learning. Traditionally, segmentation in vision tasks has been performed using convolutional neural networks (CNNs), but the transformer architecture has recently been introduced and widely investigated. We aimed to investigate the performance of deep learning models in segmentation in robot-assisted radical prostatectomy (RARP) and identify which of the architectures is superior for segmentation in robotic surgery.

Materials and methods: Intraoperative images during RARP were obtained. The dataset was randomly split into training and validation data. Segmentation of the surgical instruments, bladder, prostate, vas and seminal vesicle was performed using three CNN models (DeepLabv3, MANet, and U-Net++) and three transformers (SegFormer, BEiT, and DPT), and their performances were analyzed.

Results: The overall segmentation performance during RARP varied across different model architectures. For the CNN models, DeepLabV3 achieved a mean Dice score of 0.938, MANet scored 0.944, and U-Net++ reached 0.930. For the transformer architectures, SegFormer attained a mean Dice score of 0.919, BEiT scored 0.916, and DPT achieved 0.940. The performance of CNN models was superior to that of transformer models in segmenting the prostate, vas, and seminal vesicle.

Conclusions: Deep learning models provided accurate segmentation of the surgical instruments and anatomical structures observed during RARP. Both CNN and transformer models showed reliable predictions in the segmentation task; however, CNN models may be more suitable than transformer models for organ segmentation and may be more applicable in unusual cases. Further research with large datasets is needed.

目的:语义分割是深度学习外科应用的基础部分。传统上,视觉任务中的分割是使用卷积神经网络(CNN)进行的,但最近引入了变换器架构,并对其进行了广泛研究。我们旨在研究深度学习模型在机器人辅助根治性前列腺切除术(RARP)中的分割性能,并确定哪种架构更适合机器人手术中的分割:获取 RARP 手术过程中的术中图像。数据集随机分为训练数据和验证数据。使用三种 CNN 模型(DeepLabv3、MANet 和 U-Net++)和三种变换器(SegFormer、BEiT 和 DPT)对手术器械、膀胱、前列腺、输精管和精囊进行分割,并分析它们的性能:不同模型架构在 RARP 期间的整体分割性能各不相同。在 CNN 模型中,DeepLabV3 的平均 Dice 得分为 0.938,MANet 得分为 0.944,U-Net++ 则达到 0.930。变换器架构方面,SegFormer 的平均 Dice 得分为 0.919,BEiT 得分为 0.916,DPT 得分为 0.940。在分割前列腺、输精管和精囊方面,CNN 模型的表现优于变换器模型:结论:深度学习模型能准确分割 RARP 期间观察到的手术器械和解剖结构。在分割任务中,CNN 和变换器模型都显示出了可靠的预测结果;不过,CNN 模型可能比变换器模型更适合器官分割,也更适用于特殊情况。还需要对大型数据集进行进一步研究。
{"title":"Application of deep learning for semantic segmentation in robotic prostatectomy: Comparison of convolutional neural networks and visual transformers.","authors":"Sahyun Pak, Sung Gon Park, Jeonghyun Park, Hong Rock Choi, Jun Ho Lee, Wonchul Lee, Sung Tae Cho, Young Goo Lee, Hanjong Ahn","doi":"10.4111/icu.20240159","DOIUrl":"10.4111/icu.20240159","url":null,"abstract":"<p><strong>Purpose: </strong>Semantic segmentation is a fundamental part of the surgical application of deep learning. Traditionally, segmentation in vision tasks has been performed using convolutional neural networks (CNNs), but the transformer architecture has recently been introduced and widely investigated. We aimed to investigate the performance of deep learning models in segmentation in robot-assisted radical prostatectomy (RARP) and identify which of the architectures is superior for segmentation in robotic surgery.</p><p><strong>Materials and methods: </strong>Intraoperative images during RARP were obtained. The dataset was randomly split into training and validation data. Segmentation of the surgical instruments, bladder, prostate, vas and seminal vesicle was performed using three CNN models (DeepLabv3, MANet, and U-Net++) and three transformers (SegFormer, BEiT, and DPT), and their performances were analyzed.</p><p><strong>Results: </strong>The overall segmentation performance during RARP varied across different model architectures. For the CNN models, DeepLabV3 achieved a mean Dice score of 0.938, MANet scored 0.944, and U-Net++ reached 0.930. For the transformer architectures, SegFormer attained a mean Dice score of 0.919, BEiT scored 0.916, and DPT achieved 0.940. The performance of CNN models was superior to that of transformer models in segmenting the prostate, vas, and seminal vesicle.</p><p><strong>Conclusions: </strong>Deep learning models provided accurate segmentation of the surgical instruments and anatomical structures observed during RARP. Both CNN and transformer models showed reliable predictions in the segmentation task; however, CNN models may be more suitable than transformer models for organ segmentation and may be more applicable in unusual cases. Further research with large datasets is needed.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":"65 6","pages":"551-558"},"PeriodicalIF":2.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543645/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142591077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multi-pharmacological treatment for young subfertile males with chronic prostatitis/chronic pelvic pain syndrome. 对患有慢性前列腺炎/慢性盆腔疼痛综合征的年轻亚育男性进行多种药物治疗。
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-11-01 DOI: 10.4111/icu.20240191
Dong Hyeon Lee, Young Dong Yu

Purpose: This study evaluated the effectiveness of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) treatments using multiple pharmaceutical agents that could simultaneously preserve or enhance fertility capability.

Materials and methods: This was a single-center-based, randomized controlled study, whereas the final analysis evaluated a total 350 CP/CPPS patients (age range, 28-40 years) and 50 patients were randomly allocated to each therapeutic group, with a 1:1 ratio. The therapeutic groups consist of tadalafil (group 1, 5 mg daily), L-carnitine (group 2, 2 g daily), Serenoa repens extract (group 3, 320 mg daily), group 4 (tadalafil+L-carnitine), group 5 (tadalafil+S. repens), group 6 (L-carnitine+S. repens), and group 7 (tadalafil+L-carnitine+S. repens). The treatment outcomes at 3 months post-therapy were analyzed.

Results: At 3 months post-therapy, the mean total sperm motility was significantly improved in all groups. A normal morphology improvement was observed in L-carnitine receiving groups. The mean total score on the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) and the mean International Prostate Symptom Score (IPSS) showed the greatest reduction in intensity in group 7. Logistic regression analyses showed that group 5 and group 7 were significantly associated with improvements in total IPSS and total NIH-CPSI scores at 3 months post-therapy. Group 7 was a significant predictor for improving total sperm motility, leukocytospermia and normal form of sperm.

Conclusions: Tadalafil, carnitine, and S. repens combination therapy could be considered a feasible treatment option for CP/CPPS males with subfertility.

目的:本研究评估了使用多种药物治疗慢性前列腺炎/慢性盆腔疼痛综合征(CP/CPPS)的有效性,这些药物可同时保持或提高生育能力:这是一项基于单中心的随机对照研究,最终分析评估了350名慢性前列腺炎/慢性盆腔疼痛综合征(CP/CPPS)患者(年龄在28-40岁之间),并以1:1的比例将50名患者随机分配到每个治疗组。治疗组包括他达拉非(第1组,每天5毫克)、左旋肉碱(第2组,每天2克)、蛇床子提取物(第3组,每天320毫克)、第4组(他达拉非+左旋肉碱)、第5组(他达拉非+蛇床子)、第6组(左旋肉碱+蛇床子)和第7组(他达拉非+左旋肉碱+蛇床子)。对治疗后 3 个月的治疗结果进行了分析:结果:治疗后 3 个月,各组的平均精子总活力均有明显改善。接受左旋肉碱治疗组的精子形态正常。美国国立卫生研究院慢性前列腺炎症状指数(NIH-CPSI)的平均总分和国际前列腺症状评分(IPSS)的平均分在第 7 组中降低幅度最大。 Logistic 回归分析表明,第 5 组和第 7 组与治疗后 3 个月 IPSS 总分和 NIH-CPSI 总分的改善有显著相关性。第 7 组对精子总活力、白细胞精子症和正常形态精子的改善有明显的预测作用:结论:他达拉非、肉毒碱和补骨脂素联合疗法可被视为CP/CPPS男性不育症患者的可行治疗方案。
{"title":"Multi-pharmacological treatment for young subfertile males with chronic prostatitis/chronic pelvic pain syndrome.","authors":"Dong Hyeon Lee, Young Dong Yu","doi":"10.4111/icu.20240191","DOIUrl":"10.4111/icu.20240191","url":null,"abstract":"<p><strong>Purpose: </strong>This study evaluated the effectiveness of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) treatments using multiple pharmaceutical agents that could simultaneously preserve or enhance fertility capability.</p><p><strong>Materials and methods: </strong>This was a single-center-based, randomized controlled study, whereas the final analysis evaluated a total 350 CP/CPPS patients (age range, 28-40 years) and 50 patients were randomly allocated to each therapeutic group, with a 1:1 ratio. The therapeutic groups consist of tadalafil (group 1, 5 mg daily), L-carnitine (group 2, 2 g daily), <i>Serenoa repens</i> extract (group 3, 320 mg daily), group 4 (tadalafil+L-carnitine), group 5 (tadalafil+<i>S. repens</i>), group 6 (L-carnitine+<i>S. repens</i>), and group 7 (tadalafil+L-carnitine+<i>S. repens</i>). The treatment outcomes at 3 months post-therapy were analyzed.</p><p><strong>Results: </strong>At 3 months post-therapy, the mean total sperm motility was significantly improved in all groups. A normal morphology improvement was observed in L-carnitine receiving groups. The mean total score on the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) and the mean International Prostate Symptom Score (IPSS) showed the greatest reduction in intensity in group 7. Logistic regression analyses showed that group 5 and group 7 were significantly associated with improvements in total IPSS and total NIH-CPSI scores at 3 months post-therapy. Group 7 was a significant predictor for improving total sperm motility, leukocytospermia and normal form of sperm.</p><p><strong>Conclusions: </strong>Tadalafil, carnitine, and <i>S. repens</i> combination therapy could be considered a feasible treatment option for CP/CPPS males with subfertility.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":"65 6","pages":"567-578"},"PeriodicalIF":2.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543650/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142591080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prostate cancer theragnostics biomarkers: An update. 前列腺癌治疗生物标志物:最新进展。
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-11-01 DOI: 10.4111/icu.20240229
Sathish Kumar Am, Prabhakar Rajan, Mohammad Alkhamees, Merrel Holley, Vinoth-Kumar Lakshmanan

Biomarkers are molecules such as proteins, genes, or other substances that may be tested to determine the stage of the tumor in a patient. The role of prostate cancer biomarkers is pivotal and the combination of prostate cancer immunotherapy with efficient biomarkers has emerged as a beneficial treatment strategy and its use has increased rapidly. The two primary objectives of this current prostate cancer early detection programs were recognizing non-symptomatic individuals with prostate cancer requiring prostatic core biopsy and identifying men with prostate cancer who might benefit from definitive medical treatment. The progress that has been made so far in the identification of the biomarkers that can be used for the classification, prediction and prognostication of prostate cancer, and as major targets for its clinical intervention has been well summarized in this review.

生物标志物是指蛋白质、基因或其他物质等分子,通过检测可确定患者肿瘤的分期。前列腺癌生物标志物的作用举足轻重,前列腺癌免疫疗法与高效生物标志物的结合已成为一种有益的治疗策略,其使用也在迅速增加。目前前列腺癌早期检测项目的两个主要目标是识别需要进行前列腺核心活检的无症状前列腺癌患者,以及识别可能从明确的药物治疗中获益的前列腺癌男性患者。本综述充分总结了迄今为止在确定可用于前列腺癌分类、预测和预后的生物标志物以及作为临床干预主要目标方面所取得的进展。
{"title":"Prostate cancer theragnostics biomarkers: An update.","authors":"Sathish Kumar Am, Prabhakar Rajan, Mohammad Alkhamees, Merrel Holley, Vinoth-Kumar Lakshmanan","doi":"10.4111/icu.20240229","DOIUrl":"10.4111/icu.20240229","url":null,"abstract":"<p><p>Biomarkers are molecules such as proteins, genes, or other substances that may be tested to determine the stage of the tumor in a patient. The role of prostate cancer biomarkers is pivotal and the combination of prostate cancer immunotherapy with efficient biomarkers has emerged as a beneficial treatment strategy and its use has increased rapidly. The two primary objectives of this current prostate cancer early detection programs were recognizing non-symptomatic individuals with prostate cancer requiring prostatic core biopsy and identifying men with prostate cancer who might benefit from definitive medical treatment. The progress that has been made so far in the identification of the biomarkers that can be used for the classification, prediction and prognostication of prostate cancer, and as major targets for its clinical intervention has been well summarized in this review.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":"65 6","pages":"527-539"},"PeriodicalIF":2.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543649/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142591083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between soy products and prostate cancer: A systematic review and meta-analysis of observational studies. 豆制品与前列腺癌的关系:观察性研究的系统回顾和荟萃分析。
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-11-01 DOI: 10.4111/icu.20240186
Yiping Huang, Wenyan Wang, Jianxiang Jin

Purpose: The effect of soy products on prostate cancer (PCA) remains a topic of debate. This study aimed to investigate the association between soy products consumption and the incidence of PCA.

Materials and methods: A search was conducted in the PubMed, EBSCO, Web of Science, and Cochrane Library databases up to December 2023. The adjusted odds ratio (OR) and corresponding 95% confidence interval (CI) were used to assess the association.

Results: A total of 22 articles, comprising 1,409,213 participants, were included for this meta-analysis. The results indicate that soy products reduce the risk of PCA (OR=0.94, 95% CI=0.91-0.97, p<0.001), especially in cases of localized or low-grade PCA (OR=0.94, 95% CI=0.90-0.97, p<0.001), but exhibit no effect on non-localized or high-grade PCA (OR=0.96, 95% CI=0.91-1.01, p=0.085). Furthermore, increased consumption frequency was negatively associated with PCA risk. Specifically, soy products can reduce the risk of PCA in African Americans (OR=0.89, p=0.006) and Latinos (OR=0.93, p=0.036), but have no impact on Japanese (OR=0.99, p=0.655), Chinese (OR=0.90, p=0.155), and Whites (OR=0.96, p=0.133). Non-fermented soy products were associated with a reduction in the incidence rate of PCA (OR=0.93, 95% CI=0.90-0.96, p<0.001), while fermented soy products had no effect on the incidence rate of PCA (OR=1.10, 95% CI=0.98-1.22, p=0.096).

Conclusions: The consumption of soy products can reduce the overall risk of PCA among men. Various factors, including soy products-related factors (e.g., consumption, frequency), population-related factors (e.g., race), and PCA-related factors (e.g., PCA stage) collectively influence the effect of soy products on PCA.

目的:豆制品对前列腺癌(PCA)的影响仍是一个争论不休的话题。本研究旨在调查豆制品消费与 PCA 发病率之间的关系:截至 2023 年 12 月,在 PubMed、EBSCO、Web of Science 和 Cochrane Library 数据库中进行了检索。采用调整后的几率比(OR)和相应的 95% 置信区间(CI)来评估相关性:本次荟萃分析共纳入了 22 篇文章,共有 1,409,213 人参与。结果表明,豆制品可降低罹患 PCA 的风险(OR=0.94,95% CI=0.91-0.97,pConclusions):食用豆制品可降低男性患 PCA 的总体风险。各种因素,包括豆制品相关因素(如食用量、频率)、人口相关因素(如种族)和 PCA 相关因素(如 PCA 阶段)共同影响着豆制品对 PCA 的影响。
{"title":"Association between soy products and prostate cancer: A systematic review and meta-analysis of observational studies.","authors":"Yiping Huang, Wenyan Wang, Jianxiang Jin","doi":"10.4111/icu.20240186","DOIUrl":"10.4111/icu.20240186","url":null,"abstract":"<p><strong>Purpose: </strong>The effect of soy products on prostate cancer (PCA) remains a topic of debate. This study aimed to investigate the association between soy products consumption and the incidence of PCA.</p><p><strong>Materials and methods: </strong>A search was conducted in the PubMed, EBSCO, Web of Science, and Cochrane Library databases up to December 2023. The adjusted odds ratio (OR) and corresponding 95% confidence interval (CI) were used to assess the association.</p><p><strong>Results: </strong>A total of 22 articles, comprising 1,409,213 participants, were included for this meta-analysis. The results indicate that soy products reduce the risk of PCA (OR=0.94, 95% CI=0.91-0.97, p<0.001), especially in cases of localized or low-grade PCA (OR=0.94, 95% CI=0.90-0.97, p<0.001), but exhibit no effect on non-localized or high-grade PCA (OR=0.96, 95% CI=0.91-1.01, p=0.085). Furthermore, increased consumption frequency was negatively associated with PCA risk. Specifically, soy products can reduce the risk of PCA in African Americans (OR=0.89, p=0.006) and Latinos (OR=0.93, p=0.036), but have no impact on Japanese (OR=0.99, p=0.655), Chinese (OR=0.90, p=0.155), and Whites (OR=0.96, p=0.133). Non-fermented soy products were associated with a reduction in the incidence rate of PCA (OR=0.93, 95% CI=0.90-0.96, p<0.001), while fermented soy products had no effect on the incidence rate of PCA (OR=1.10, 95% CI=0.98-1.22, p=0.096).</p><p><strong>Conclusions: </strong>The consumption of soy products can reduce the overall risk of PCA among men. Various factors, including soy products-related factors (e.g., consumption, frequency), population-related factors (e.g., race), and PCA-related factors (e.g., PCA stage) collectively influence the effect of soy products on PCA.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":"65 6","pages":"540-550"},"PeriodicalIF":2.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543648/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142591078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence and economic burden of male anogenital wart in Korea: A population-based big data analysis from 2007 to 2018. 韩国男性生殖器疣的发病率和经济负担:2007年至2018年基于人口的大数据分析。
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-11-01 DOI: 10.4111/icu.20240274
Hong Chung, Jin Bong Choi, Sooyoun Kim, Seung-Ju Lee, Sangrak Bae

Purpose: To investigate the prevalence of anogenital warts (AGW) caused by human papillomavirus in men and the characteristics and changes of the disease in Korea.

Materials and methods: From 2007 to 2018, male AGW corresponding to the International Classification of Disease-10 A63.0 were targeted. Through a big data analysis of the Health Insurance Review & Assessment Service, data of patients diagnosed with AGW as either the main or secondary diagnosis were extracted. The overall prevalence and prevalence by age were calculated through the population by year and the population by 5-year-old unit of the National Statistical Office. Additionally, the amount accrued through the disease code was confirmed and compared as AGW-related medical expenses.

Results: The annual number of patients increased by 3.5 times from 32,709 in 2007 to 114,734 in 2018. Additionally, the annual prevalence increased by 3.34 times from 132.83 per 100,000 to 443.57. The age-specific prevalence was the highest among the 25- to 29-year age group. The highest prevalence was observed in the 25- to 29-year age group in 2018 (1,492.15 per 100,000), and the lowest was noted in the 10- to 14-year age group in 2014 (7.28 per 100,000). AGW-related medical expenses increased by approximately 9.76 times from US$ 2,789,215.1 in 2007 to US$ 27,227,254.9 in 2018.

Conclusions: In Korea, cases of male AGW are increasing yearly, with the 25- to 29-year age group having the highest prevalence. Medical costs related to AGW are also increasing tenfold. For male AGW, further studies and national interventions are needed.

目的:调查韩国男性由人类乳头瘤病毒引起的生殖器疣(AGW)的患病率以及该疾病的特点和变化:2007年至2018年,以国际疾病分类-10 A63.0对应的男性AGW为对象。通过对健康保险审查与评估服务的大数据分析,提取了以 AGW 为主要诊断或辅助诊断的患者数据。通过国家统计局按年份划分的人口和按 5 岁为单位划分的人口,计算出总患病率和按年龄划分的患病率。此外,通过疾病代码确认并比较了与 AGW 相关的医疗费用:年患者人数从 2007 年的 32 709 人增至 2018 年的 114 734 人,增长了 3.5 倍。此外,年患病率从每 10 万人中 132.83 例增加到 443.57 例,增加了 3.34 倍。25至29岁年龄组的发病率最高。2018年,25至29岁年龄组的患病率最高(每10万人中有1492.15人),2014年,10至14岁年龄组的患病率最低(每10万人中有7.28人)。与 AGW 相关的医疗费用从 2007 年的 2,789,215.1 美元增至 2018 年的 27,227,254.9 美元,增长了约 9.76 倍:在韩国,男性 AGW 病例逐年增加,25 至 29 岁年龄组发病率最高。与 AGW 相关的医疗费用也增加了十倍。对于男性 AGW,需要进一步研究和国家干预。
{"title":"Prevalence and economic burden of male anogenital wart in Korea: A population-based big data analysis from 2007 to 2018.","authors":"Hong Chung, Jin Bong Choi, Sooyoun Kim, Seung-Ju Lee, Sangrak Bae","doi":"10.4111/icu.20240274","DOIUrl":"10.4111/icu.20240274","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the prevalence of anogenital warts (AGW) caused by human papillomavirus in men and the characteristics and changes of the disease in Korea.</p><p><strong>Materials and methods: </strong>From 2007 to 2018, male AGW corresponding to the International Classification of Disease-10 A63.0 were targeted. Through a big data analysis of the Health Insurance Review & Assessment Service, data of patients diagnosed with AGW as either the main or secondary diagnosis were extracted. The overall prevalence and prevalence by age were calculated through the population by year and the population by 5-year-old unit of the National Statistical Office. Additionally, the amount accrued through the disease code was confirmed and compared as AGW-related medical expenses.</p><p><strong>Results: </strong>The annual number of patients increased by 3.5 times from 32,709 in 2007 to 114,734 in 2018. Additionally, the annual prevalence increased by 3.34 times from 132.83 per 100,000 to 443.57. The age-specific prevalence was the highest among the 25- to 29-year age group. The highest prevalence was observed in the 25- to 29-year age group in 2018 (1,492.15 per 100,000), and the lowest was noted in the 10- to 14-year age group in 2014 (7.28 per 100,000). AGW-related medical expenses increased by approximately 9.76 times from US$ 2,789,215.1 in 2007 to US$ 27,227,254.9 in 2018.</p><p><strong>Conclusions: </strong>In Korea, cases of male AGW are increasing yearly, with the 25- to 29-year age group having the highest prevalence. Medical costs related to AGW are also increasing tenfold. For male AGW, further studies and national interventions are needed.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":"65 6","pages":"579-586"},"PeriodicalIF":2.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543654/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142591081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dasatinib induces apoptosis and autophagy by suppressing the PI3K/Akt/mTOR pathway in bladder cancer cells. 达沙替尼通过抑制膀胱癌细胞中的PI3K/Akt/mTOR通路诱导细胞凋亡和自噬。
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-11-01 DOI: 10.4111/icu.20240250
Jin-Nyoung Ho, Seok-Soo Byun, Danhyo Kim, Hoyoung Ryu, Sangchul Lee

Purpose: Bladder cancer is a common genitourinary malignant disease worldwide. Dasatinib is a small molecule inhibitor of Src family kinases. We investigated the anticancer effect and putative molecular mechanisms of dasatinib on T24 and cisplatin-resistant T24R2 human bladder cancer cells.

Materials and methods: Cell proliferation was measured using Cell Counting Kit-8 (CCK-8) and colony formation in dasatinib treated bladder cancer cells. Flow cytometry was used to determined cell cycle arrest and apoptosis. The expression of apoptosis and autophagy related proteins were detected by western blot analysis.

Results: In bladder cancer cells, dasatinib significantly reduced cell proliferation, colony formation, and induced G1-phase arrest. Dasatinib triggered apoptosis along with an increased expression of apoptosis-related genes (caspases, PARP, and cytochrome c). Down-regulation of Bcl-2 and up-regulation of Bad, which are hallmarks of apoptosis, were found to play a dominant role in mediating the effects of dasatinib treatment. We further showed that dasatinib inhibits p-Src, p-PI3K, p-Akt, and p-mTOR in bladder cancer cells. Dasatinib also increased the expression of markers of autophagy flux such as LC3-II and p62.

Conclusions: These results confirmed that dasatinib is a potent chemotherapeutic drug which induces apoptosis and autophagy by suppressing the PI3K/Akt/mTOR pathway in bladder cancer cells.

目的:膀胱癌是全球常见的泌尿生殖系统恶性疾病。达沙替尼是一种小分子 Src 家族激酶抑制剂。我们研究了达沙替尼对T24和顺铂耐药的T24R2人膀胱癌细胞的抗癌作用和可能的分子机制:使用细胞计数试剂盒-8(CCK-8)测定达沙替尼处理的膀胱癌细胞的细胞增殖和集落形成。流式细胞术用于测定细胞周期停滞和细胞凋亡。结果表明,达沙替尼对膀胱癌细胞有抑制作用:结果:在膀胱癌细胞中,达沙替尼可明显减少细胞增殖和集落形成,并诱导细胞G1期停滞。达沙替尼可诱导细胞凋亡,同时增加凋亡相关基因(caspases、PARP和细胞色素c)的表达。研究发现,Bcl-2的下调和Bad的上调是细胞凋亡的标志,它们在达沙替尼治疗的效应中起着主导作用。我们进一步发现,达沙替尼抑制膀胱癌细胞中的p-Src、p-PI3K、p-Akt和p-mTOR。达沙替尼还增加了LC3-II和p62等自噬通量标志物的表达:这些结果证实达沙替尼是一种有效的化疗药物,它能通过抑制膀胱癌细胞的PI3K/Akt/mTOR通路诱导细胞凋亡和自噬。
{"title":"Dasatinib induces apoptosis and autophagy by suppressing the PI3K/Akt/mTOR pathway in bladder cancer cells.","authors":"Jin-Nyoung Ho, Seok-Soo Byun, Danhyo Kim, Hoyoung Ryu, Sangchul Lee","doi":"10.4111/icu.20240250","DOIUrl":"10.4111/icu.20240250","url":null,"abstract":"<p><strong>Purpose: </strong>Bladder cancer is a common genitourinary malignant disease worldwide. Dasatinib is a small molecule inhibitor of Src family kinases. We investigated the anticancer effect and putative molecular mechanisms of dasatinib on T24 and cisplatin-resistant T24R2 human bladder cancer cells.</p><p><strong>Materials and methods: </strong>Cell proliferation was measured using Cell Counting Kit-8 (CCK-8) and colony formation in dasatinib treated bladder cancer cells. Flow cytometry was used to determined cell cycle arrest and apoptosis. The expression of apoptosis and autophagy related proteins were detected by western blot analysis.</p><p><strong>Results: </strong>In bladder cancer cells, dasatinib significantly reduced cell proliferation, colony formation, and induced G1-phase arrest. Dasatinib triggered apoptosis along with an increased expression of apoptosis-related genes (caspases, PARP, and cytochrome c). Down-regulation of Bcl-2 and up-regulation of Bad, which are hallmarks of apoptosis, were found to play a dominant role in mediating the effects of dasatinib treatment. We further showed that dasatinib inhibits p-Src, p-PI3K, p-Akt, and p-mTOR in bladder cancer cells. Dasatinib also increased the expression of markers of autophagy flux such as LC3-II and p62.</p><p><strong>Conclusions: </strong>These results confirmed that dasatinib is a potent chemotherapeutic drug which induces apoptosis and autophagy by suppressing the PI3K/Akt/mTOR pathway in bladder cancer cells.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":"65 6","pages":"593-602"},"PeriodicalIF":2.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543652/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142591079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pseudoepitheliomatous hyperplasia of the penis: A rare mimic of squamous cell carcinoma. 阴茎假上皮细胞增生症:鳞状细胞癌的罕见假象。
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-11-01 DOI: 10.4111/icu.20240253
Mohammed Taher Mujahid, Vikas Kumar Panwar, Gautam Shubhankar, Ankur Mittal
{"title":"Pseudoepitheliomatous hyperplasia of the penis: A rare mimic of squamous cell carcinoma.","authors":"Mohammed Taher Mujahid, Vikas Kumar Panwar, Gautam Shubhankar, Ankur Mittal","doi":"10.4111/icu.20240253","DOIUrl":"10.4111/icu.20240253","url":null,"abstract":"","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":"65 6","pages":"603-605"},"PeriodicalIF":2.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543647/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142591084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Investigative and Clinical Urology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1